| Autor: |
Koguchi ‐ Yoshioka, H., Okiyama, N., Iwamoto, K., Matsumura, Y., Ogawa, T., Inoue, S., Watanabe, R., Fujimoto, M. |
| Předmět: |
|
| Zdroj: |
British Journal of Dermatology; Nov2017, Vol. 177 Issue 5, p1442-1446, 5p |
| Abstrakt: |
Autoantibodies to melanoma differentiation-associated protein 5 ( MDA5) are associated with a subset of patients with dermatomyositis ( DM) who have rapidly progressive interstitial lung disease ( RP- ILD) with poor prognosis. Intensive immunosuppressive therapy is initiated before irreversible lung damage can occur; however, there are few lines of evidence for the treatment of RP- ILD. Here, we report three cases of anti- MDA5 antibody-associated DM with RP- ILD in which the patients were treated with combined-modality therapy, including high-dose prednisolone, tacrolimus, intravenous cyclophosphamide and intravenous immunoglobulin ( IVIG). In all three cases, serum ferritin levels, which are known to represent the disease activity of RP- ILD, were decreased after IVIG administration. IVIG might contribute to the control of the disease activity of anti- MDA5 antibody-positive DM. Moreover, palmar violaceous macules/papules around the interphalangeal joints, which was observed in all three cases in the incipient stage, might be a useful sign in suggesting a diagnosis of anti- MDA5 antibody-associated DM. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text